BRPI0407732A - pirimidinas e triazinas inibidoras da replicação de hiv - Google Patents

pirimidinas e triazinas inibidoras da replicação de hiv

Info

Publication number
BRPI0407732A
BRPI0407732A BRPI0407732-6A BRPI0407732A BRPI0407732A BR PI0407732 A BRPI0407732 A BR PI0407732A BR PI0407732 A BRPI0407732 A BR PI0407732A BR PI0407732 A BRPI0407732 A BR PI0407732A
Authority
BR
Brazil
Prior art keywords
hiv replication
triazines
pyrimidines
replication inhibiting
inhibiting pyrimidines
Prior art date
Application number
BRPI0407732-6A
Other languages
English (en)
Inventor
Jerome Emile George Guillemont
Elisabeth Therese Jea Pasquier
Jan Heeres
Kurt Hertogs
Eva Bettens
Paulus Joannes Lewi
Marc Rene De Jonge
Lucien Maria Henricus Koymans
Frederik Frans Desire Daeyaert
Hendrik Maarten Vinkes
Paul Adriaan Jan Janssen
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Publication of BRPI0407732A publication Critical patent/BRPI0407732A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

"PIRIMIDINAS E TRIAZINAS INIBIDORAS DA REPLICAçãO DE HIV". Esta invenção refere-se a inibidores da replicação de HIV de fórmula (I). Aos N-óxidos, aos sais de adição farmaceuticamante aceitáveis, às aminas quaternárias e às formas estereoquimicamente isoméricas dos mesmos, sua utilização como um medicamento, seus processos para a preparação de composições farmacêuticas compreendendo os mesmos.
BRPI0407732-6A 2003-02-20 2004-02-20 pirimidinas e triazinas inibidoras da replicação de hiv BRPI0407732A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03100411 2003-02-20
US47501203P 2003-06-02 2003-06-02
PCT/EP2004/050177 WO2004074262A1 (en) 2003-02-20 2004-02-20 Hiv replication inhibiting pyrimidines and triazines

Publications (1)

Publication Number Publication Date
BRPI0407732A true BRPI0407732A (pt) 2006-02-14

Family

ID=32910137

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0407732-6A BRPI0407732A (pt) 2003-02-20 2004-02-20 pirimidinas e triazinas inibidoras da replicação de hiv
BRPI0407741A BRPI0407741B8 (pt) 2003-02-20 2004-02-20 pirimidinas e triazinas de inibição de replicação de hiv

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI0407741A BRPI0407741B8 (pt) 2003-02-20 2004-02-20 pirimidinas e triazinas de inibição de replicação de hiv

Country Status (27)

Country Link
US (2) US7442705B2 (pt)
EP (2) EP1603887B1 (pt)
JP (2) JP4586014B2 (pt)
KR (2) KR20050094896A (pt)
CN (2) CN100572364C (pt)
AP (1) AP2005003373A0 (pt)
AR (2) AR044500A1 (pt)
AT (2) ATE361915T1 (pt)
AU (2) AU2004213186B2 (pt)
BR (2) BRPI0407732A (pt)
CA (2) CA2516699C (pt)
CL (2) CL2004000303A1 (pt)
CY (1) CY1106788T1 (pt)
DE (2) DE602004032321D1 (pt)
DK (1) DK1597238T3 (pt)
EA (2) EA010423B1 (pt)
ES (1) ES2287734T3 (pt)
HR (2) HRP20050821A2 (pt)
IL (2) IL169596A (pt)
MX (2) MXPA05008866A (pt)
MY (1) MY138308A (pt)
NO (2) NO20054311L (pt)
NZ (2) NZ541601A (pt)
PL (2) PL227295B1 (pt)
PT (1) PT1597238E (pt)
TW (2) TW200500346A (pt)
WO (2) WO2004074261A1 (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
HRP20050089B1 (hr) 2002-07-29 2015-06-19 Rigel Pharmaceuticals Upotreba 2,4 pirimidindiaminskog spoja za proizvodnju lijeka za lijeäśenje ili sprjeäśavanje autoimunosne bolesti
CL2004000303A1 (es) * 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih.
JP4886511B2 (ja) 2003-07-30 2012-02-29 ライジェル ファーマシューティカルズ， インコーポレイテッド ２，４−ピリミジンジアミン化合物による自己免疫疾患の治療または予防方法
EP2543376A1 (en) 2004-04-08 2013-01-09 Targegen, Inc. Benzotriazine inhibitors of kinases
AU2005276974B2 (en) 2004-08-25 2012-08-02 Targegen, Inc. Heterocyclic compounds and methods of use
ATE540035T1 (de) 2004-11-24 2012-01-15 Rigel Pharmaceuticals Inc Spiro-2,4-pyrimidindiamin-verbindungen und ihre verwendungen
CN101115761B (zh) 2005-01-19 2012-07-18 里格尔药品股份有限公司 2,4-嘧啶二胺化合物的前药及其应用
AU2006254840B2 (en) 2005-06-08 2012-08-02 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US8133900B2 (en) 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
NZ567851A (en) 2005-11-01 2011-09-30 Targegen Inc Bi-aryl meta-pyrimidine inhibitors of kinases
US8604042B2 (en) 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
ES2622493T3 (es) 2006-02-24 2017-07-06 Rigel Pharmaceuticals, Inc. Composiciones y métodos para la inhibición de la ruta de JAK
ES2523863T3 (es) * 2006-12-29 2014-12-02 Janssen R&D Ireland Pirimidinas 5,6-sustituidas inhibidoras del VIH
BRPI0720858B8 (pt) * 2006-12-29 2021-05-25 Janssen R & D Ireland pirimidinas 6-substituídas inibidoras de hiv e composição farmacêutica que as compreende
MX2010012703A (es) 2008-05-21 2010-12-21 Ariad Pharma Inc Derivados fosforosos como inhibidores de cinasa.
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
US7737157B2 (en) * 2008-08-29 2010-06-15 Hutchison Medipharma Enterprises Limited Pyrimidine compounds
GEP20135793B (en) 2008-09-11 2013-03-25 Pfizer Heteroaryls amide derivatives and their use as glucokinase activators
AR074209A1 (es) 2008-11-24 2010-12-29 Boehringer Ingelheim Int Derivados de pirimidina utiles para el tratamiento del cancer
TWI491605B (zh) 2008-11-24 2015-07-11 Boehringer Ingelheim Int 新穎化合物
DK2406253T3 (da) 2009-03-11 2013-08-12 Pfizer Benzofuranylderivater anvendt som glucokinase-inhibitorer
WO2012060847A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
US9249124B2 (en) 2011-03-30 2016-02-02 H. Lee Moffitt Cancer Center And Research Institute, Inc. Aurora kinase inhibitors and methods of making and using thereof
BR112013027734A2 (pt) 2011-05-04 2017-08-08 Ariad Pharma Inc compostos para a inibição de proliferação celular em cânceres impulsionados pelo egfr, método e composição farmacêutica
GB201119358D0 (en) 2011-11-10 2011-12-21 Lewi Paulus J Disubstituted triazine dimers for treatment and/or prevention of infectious diseases
GB201204756D0 (en) 2012-03-19 2012-05-02 Lewi Paulus J Triazines with suitable spacers for treatment and/or prevention of HIV infections
AU2013204563B2 (en) 2012-05-05 2016-05-19 Takeda Pharmaceutical Company Limited Compounds for inhibiting cell proliferation in EGFR-driven cancers
WO2014072419A1 (en) 2012-11-08 2014-05-15 Universiteit Antwerpen Novel anti-hiv compounds
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
CN108602802B (zh) * 2016-07-26 2020-01-21 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白酪氨酸激酶活性的氨基嘧啶类化合物
CN106749203B (zh) * 2016-11-28 2020-04-10 洛阳聚慧医药科技有限公司 一种嘧啶类杂环化合物、嘧啶类杂环化合物盐以及制备方法和应用
RS65019B1 (sr) 2019-05-10 2024-01-31 Deciphera Pharmaceuticals Llc Fenilaminopirimidin amidni inhibitori autofagije i postupci njihove primene
AU2020274011B2 (en) 2019-05-10 2024-02-15 Deciphera Pharmaceuticals, Llc Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof
CN119241444A (zh) 2019-06-17 2025-01-03 德西费拉制药有限责任公司 氨基嘧啶酰胺自噬抑制剂及其使用方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US5691364A (en) 1995-03-10 1997-11-25 Berlex Laboratories, Inc. Benzamidine derivatives and their use as anti-coagulants
EP0862463A1 (en) 1995-11-23 1998-09-09 Janssen Pharmaceutica N.V. Solid mixtures of cyclodextrins prepared via melt-extrusion
NO311614B1 (no) * 1996-10-01 2001-12-17 Janssen Pharmaceutica Nv Substituerte diamino-1,3,5-triazinderivater
GB9705361D0 (en) 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
NZ506679A (en) * 1998-03-27 2002-11-26 Janssen Pharmaceutica Nv HIV inhibiting pyrimidine derivatives
EP0945447A1 (en) 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. Trisubstituted 1,3,5-triazine derivatives for treatment of HIV infections
SK287269B6 (sk) * 1998-11-10 2010-05-07 Janssen Pharmaceutica N. V. Derivát pyrimidínu, jeho použitie, spôsob jeho prípravy a farmaceutická kompozícia, kombinácia a produkt s jeho obsahom
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
PT1169038E (pt) 1999-04-15 2012-10-26 Bristol Myers Squibb Co Inibidores cíclicos da proteína tirosina cinase
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
JP4919566B2 (ja) * 1999-09-24 2012-04-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗ウイルス組成物
ATE396978T1 (de) * 1999-10-07 2008-06-15 Amgen Inc Triazin-kinase-hemmer
JP5230050B2 (ja) 2000-05-08 2013-07-10 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｈｉｖ複製阻害剤
AU2002216650A1 (en) 2000-10-31 2002-05-15 Lynn Bonham Triazine derivatives as lpaat-b inhibitors and uses thereof
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
AU2003244463A1 (en) * 2002-02-05 2003-09-02 Yamanouchi Pharmaceutical Co., Ltd. 2,4,6-triamino-1,3,5-triazine derivative
AR039540A1 (es) * 2002-05-13 2005-02-23 Tibotec Pharm Ltd Compuestos microbicidas con contenido de pirimidina o triazina
JP4529685B2 (ja) * 2002-06-28 2010-08-25 アステラス製薬株式会社 ジアミノピリミジンカルボキサミド誘導体
HRP20050089B1 (hr) * 2002-07-29 2015-06-19 Rigel Pharmaceuticals Upotreba 2,4 pirimidindiaminskog spoja za proizvodnju lijeka za lijeäśenje ili sprjeäśavanje autoimunosne bolesti
CL2004000303A1 (es) 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih.

Also Published As

Publication number Publication date
CL2004000306A1 (es) 2005-04-08
EA200501326A1 (ru) 2006-02-24
CY1106788T1 (el) 2012-05-23
IL169596A0 (en) 2007-07-04
JP2006518357A (ja) 2006-08-10
EA011256B1 (ru) 2009-02-27
WO2004074261A1 (en) 2004-09-02
EP1603887A1 (en) 2005-12-14
JP4586014B2 (ja) 2010-11-24
CN1751031A (zh) 2006-03-22
HRP20050820A2 (en) 2006-11-30
JP2006518356A (ja) 2006-08-10
US7585870B2 (en) 2009-09-08
EP1603887B1 (en) 2011-04-20
CN1751031B (zh) 2010-07-21
US20060194804A1 (en) 2006-08-31
TW200510339A (en) 2005-03-16
DK1597238T3 (da) 2007-09-10
IL169596A (en) 2017-02-28
IL169647A0 (en) 2007-07-04
AU2004213187A1 (en) 2004-09-02
US7442705B2 (en) 2008-10-28
AU2004213186B2 (en) 2009-10-01
CL2004000303A1 (es) 2005-04-08
TW200500346A (en) 2005-01-01
CA2516699C (en) 2011-07-12
NO20054311D0 (no) 2005-09-19
BRPI0407741A (pt) 2006-02-14
NZ541601A (en) 2007-09-28
CN100572364C (zh) 2009-12-23
EP1597238A1 (en) 2005-11-23
NO20054312L (no) 2005-11-16
KR20050099994A (ko) 2005-10-17
BRPI0407741B8 (pt) 2021-05-25
CA2516699A1 (en) 2004-09-02
IL169647A (en) 2013-05-30
AR044499A1 (es) 2005-09-14
ATE361915T1 (de) 2007-06-15
WO2004074262A1 (en) 2004-09-02
DE602004006383D1 (de) 2007-06-21
EP1597238B1 (en) 2007-05-09
DE602004032321D1 (de) 2011-06-01
MXPA05008867A (es) 2005-10-05
NO20054311L (no) 2005-10-27
MXPA05008866A (es) 2005-10-05
NO20054312D0 (no) 2005-09-19
CA2516589A1 (en) 2004-09-02
EA010423B1 (ru) 2008-08-29
PL378064A1 (pl) 2006-02-20
US20060142571A1 (en) 2006-06-29
PL378136A1 (pl) 2006-03-06
AU2004213186A1 (en) 2004-09-02
HRP20050821A2 (en) 2006-11-30
NZ542428A (en) 2007-11-30
PT1597238E (pt) 2007-08-08
ATE506353T1 (de) 2011-05-15
ES2287734T3 (es) 2007-12-16
AP2005003373A0 (en) 2005-09-30
DE602004006383T2 (de) 2008-01-10
CA2516589C (en) 2012-04-17
JP4586013B2 (ja) 2010-11-24
BRPI0407741B1 (pt) 2018-05-29
MY138308A (en) 2009-05-29
KR20050094896A (ko) 2005-09-28
AR044500A1 (es) 2005-09-14
PL226954B1 (pl) 2017-10-31
EA200501327A1 (ru) 2006-02-24
AU2004213187B2 (en) 2009-11-05
CN1751030A (zh) 2006-03-22
PL227295B1 (pl) 2017-11-30

Similar Documents

Publication Publication Date Title
BRPI0407732A (pt) pirimidinas e triazinas inibidoras da replicação de hiv
AR024227A1 (es) Pirimidinas inhibidoras de replicacion de hiv, un proceso para su preparacion, el uso de las mismas para la manufactura de un medicamento, composiciones farmaceuticas, y un proceso para prepararlas
BRPI0407306A (pt) 1,2,4- triazinas de inibição de hiv
CO2022012884A2 (es) Compuestos de amino pirimidina fusionados
WO2001085700A3 (en) Hiv replication inhibiting pyrimidines and triazines
BR0209267A (pt) Pirimidinas fundidas como antagonistas do fator de liberação de corticotropina (crf)
BRPI0507065A (pt) derivados de quinolina e seu uso como inibidores micobacterianos
BR0213562A (pt) Benzimidazóis e análogos e seu uso como inibidores de cinases de proteìna
BRPI0414791A (pt) derivados de purina inibidores da replicação do hiv
BRPI0414570A (pt) derivados de 2-piridona como inibidores de elastase de neutrófilo e seu uso
BR0313041A (pt) Compostos; composições farmacêuticas; método para o tratamento e/ou profilaxia de doenças que estão associadas à modulação dos receptores de cb1; e uso de compostos
BRPI0606313A2 (pt) derivados de 4-(1h-indol-3-il)-pirimidin-2-ilamina, processo para sua preparação e seu uso em terapia
UY30183A1 (es) Derivados de quinolina
CY1111102T1 (el) 2-(4-κυανοφαινυλ)-6-υδροξυλαμινοπυριμιδινες που αναστελλουν τον hiv
BR0317658A (pt) Derivados de 1-piperidin-4-il-4-pirrolidin-3-il-piperazina substituìda e seu emprego como antagonistas de neuroquinina
BR112022007680A2 (pt) Derivados de n-(heteroaril)quinazolin-2-amina como inibidores de lrrk2, composições farmacêuticas, e usos dos mesmos
BRPI0508107A (pt) derivados de indazol e composições farmacêuticas contendo os mesmos
MX2022012881A (es) Inhibidores de replicacion del virus de inmunodeficiencia humana.
BRPI0511778A (pt) derivados da naftalina úteis como ligantes do receptor 3 da histamina
BRPI0517792A (pt) macrolonas - quinolonas amino-substituìdas
BRPI0417609B8 (pt) derivados de 3-ciano-quinolina com atividade antiproliferativa, seu processo de preparação e uso e composição farmacêutica que os compreende
BRPI0511999A (pt) compostos como antagonistas de ccr5
MX2020009711A (es) Combinacion de quinolin-4-carboxamidas y derivados de benzonaftiridina como combinacion de farmacos antipaludicos.
DK1411956T3 (da) Anvendelse af oversulfaterede polysaccharider som inhibitorer af HIV
DK1818048T3 (da) Farmaceutiske formuleringer af alifatiske aminpolymerer og metoder til deres fremstilling

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25D Requested change of name of applicant approved

Owner name: TIBOTEC PHARMACEUTICALS (IE)

B25D Requested change of name of applicant approved

Owner name: JANSSEN R AND D IRELAND (IE)

B25A Requested transfer of rights approved

Owner name: JANSSEN SCIENCES IRELAND UC (IE)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL